DAVID ZOOK

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

H.R. 1038

Access to Life-Saving Medicine Act

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Original LDA source filings (17)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2008 · third_quarter · Q3

Firm income: —Client expense: $166,741Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

MED

Medical/Disease Research/Clinical Labs

Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283) Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and

Source: Senate LDA

Show 18 more cited filings

H.R. 1283

Arthritis Prevention, Control, and Cure Act of 2008

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

H.R. 1283

Arthritis Prevention, Control, and Cure Act of 2008

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R. 1283)

H.R. 1283

Arthritis Prevention, Control, and Cure Act of 2008

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283) Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and

H.R. 1956

Patient Protection and Innovative Biologic Medicines Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

H.R. 1956

Patient Protection and Innovative Biologic Medicines Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

H.R. 1956

Patient Protection and Innovative Biologic Medicines Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

H.R. 5629

Pathway for Biosimilars Act

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

H.R. 5629

Pathway for Biosimilars Act

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

H.R. 5629

Pathway for Biosimilars Act

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

S. 1695

Biologics Price Competition and Innovation Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

S. 1695

Biologics Price Competition and Innovation Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

S. 1695

Biologics Price Competition and Innovation Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocate for increased appropriations for the Center for Disease Control & Prevention and the National Institues of Health Provided comments on following bills: Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695)

S. 3230

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2009

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

Arthritis Prevention, Control, and Cure Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R. 1283)

Arthritis Prevention, Control, and Cure Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

Arthritis Prevention, Control, and Cure Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R. 1283)

Arthritis Prevention, Control, and Cure Act of 2007

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283) Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and

H.R. 2638

Small Business Expensing Permanency Act of 2003

Client: ARTHRITIS FOUNDATION · Firm: ARTHRITIS FOUNDATION

Cited source text

Advocated for the increased appropriations for the Center for Disease Control & Prevention and the National Institutes of Health and supported the following bills: H.R. 2638 S. 3230 Patient Protection and Innovative Biologic Medicines Act (H.R. 1956) Pathway for Biosimilars Act (H.R. 5629) Access to Life-Saving Medicine Act (H.R. 1038) Biologics Price Competition and Innovation (S. 1695) Support for and passage of the Arthritis Prevention, Control & Cure Act (S.626/H.R.1283)

Show 13 more original filings

2006 · year_end · YY

Firm income: —Client expense: $320,000Open original LDA filing ↗

Assigned issues and filing targets (0 issues)

Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

2006 · mid_year · MM

Firm income: —Client expense: $320,000Open original LDA filing ↗

Assigned issues and filing targets (0 issues)

Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

2005 · year_end · YY

Firm income: —Client expense: $320,000Open original LDA filing ↗

Assigned issues and filing targets (0 issues)

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

2003 · year_end · YY

Firm income: —Client expense: $250,000Open original LDA filing ↗

Assigned issues and filing targets (0 issues)

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

2002 · year_end · YA

Firm income: —Client expense: $253,000Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

HCR

Health Issues

Advocated for increased funding for the Center for Disease Control and Prevention and the National Institutes of Health. Also, involved in managed care reform, Medicare and Social Security disability issues.

INS

Insurance

Managed care reform Access to specialty medical care.

MED

Medical/Disease Research/Clinical Labs

Available of specialty medicare care. Increased funding for arthritis research at the National Institues of Health NIH).

2002 · mid_year · MM

Firm income: —Client expense: $253,000Open original LDA filing ↗

Assigned issues and filing targets (6 issues)

POS

Postal

Postal rates and issues as they relate to non-profit organizations

MED

Medical/Disease Research/Clinical Labs

Availability of specialty medical care Increased funding for arthritis research at the National Institutes of Health (NIH).

MMM

Medicare/Medicaid

Medicare managed care and benefits issues and Medicare prescription drug benefits proposals

HCR

2001 · mid_year · MM

Firm income: —Client expense: $200,000Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

POS

Postal

Postal rates and issues as they relate to non-profit organizations

INS

Insurance

Managed care reform Access to specialty medical care

HCR

Health Issues

Advocated for increased funding for the Center for Disease Control and Prevention and the National Institutes of Health. Also involved in managed care reform, Medicare and Social Security disability issues.

MMM

2001 · mid_year · MM

Firm income: —Client expense: $150,000Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

HCR

Health Issues

Advocated for increased funding for the Centers for Disease Control and Prevention and the National Institutes of Health. Also involved in managed care reform, Medicare and Social Security disability issues.

MMM

Medicare/Medicaid

Medicare managed care and benefits issues Medicare prescription drug benefit proposal

INS

Insurance

Managed care reform Access to specialty medical care

BUD

2000 · year_end · YY

Firm income: —Client expense: $150,000Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

HCR

Health Issues

MMM

Medicare/Medicaid

Medicare managed care and benefits issues Medicare prescription drug benefit proposal

INS

Insurance

Managed care reform Access to specialty medical care

BUD

2000 · year_end · YY

Firm income: —Client expense: $150,000Open original LDA filing ↗

Assigned issues and filing targets (5 issues)

HCR

Health Issues

MMM

Medicare/Medicaid

Medicare managed care and benefits issues Medicare prescription drug benefit proposal

POS

Postal

Postal rates and issues as they relate to non-profit organizations.

INS

2000 · mid_year · MM

Firm income: —Client expense: $150,000Open original LDA filing ↗

Assigned issues and filing targets (0 issues)

Filing targets: Agency for Healthcare Research & Quality (AHRQ), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, U.S. Postal Service (USPS)

1999 · year_end · YY

Firm income: —Client expense: $120,000Open original LDA filing ↗

Assigned issues and filing targets (0 issues)

Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Social Security Administration (SSA), U.S. Postal Service (USPS)